1. Clinically significant microvascular complications: nephropathy (estimated glomerular filtration rate below 40 ml/min), neuropathy (especially diagnosed gastroparesis) or severe proliferative retinopathy as judged by the investigator. 
2. Recent (< 3 months) acute macrovascular event e.g. acute coronary syndrome or cardiac surgery. 
3. Ongoing pregnancy. 
4. Severe hypoglycemic episode within 1 month of screening. 
5. Agents affecting gastric emptying (Motilium®, Prandase®, Victoza®, Byetta® and Symlin®) as well as oral anti-diabetic agents (Metformin, SGLT-2 inhibitors and DPP-4 inhibitors) if not at a stable dose for 3 months. Otherwise, these medications are acceptable and will be kept stable during the entire protocol. 
6. Oral steroids unless patients present a low stable dose (e.g. 10 mg or less of prednisone per day or physiological doses, less than 35 mg/day, of hydrocortisone Cortef®). Inhale steroids at stable dose in the last month are acceptable. 
7. Other serious medical illness likely to interfere with study participation or with the ability to complete the trial by the judgment of the investigator (e.g. unstable psychiatric condition). 
8. Failure to comply with team's recommendations (e.g. not willing to change pump parameters, follow algorithm's suggestions, etc). 
9. Living or planned travel outside Montreal (> 1h of driving) area during closed-loop procedures.       
    

NCT02416765_exc_T10
Condition
microvascular complications
NCT02416765_exc_T11
Measurement
estimated glomerular filtration rate
NCT02416765_exc_T12
Value
below 40 ml/min
NCT02416765_exc_T13
Condition
nephropathy
NCT02416765_exc_T14
Condition
neuropathy
NCT02416765_exc_T15
Condition
gastroparesis
NCT02416765_exc_T16
Condition
severe proliferative retinopathy
NCT02416765_exc_T18
Qualifier
as judged by the investigator
NCT02416765_exc_T19
Scope
nephropathy (estimated glomerular filtration rate below 40 ml/min), neuropathy (especially diagnosed gastroparesis) or severe proliferative retinopathy
NCT02416765_exc_T20
Temporal
< 3 months
NCT02416765_exc_T21
Temporal
Recent
NCT02416765_exc_T22
Condition
acute macrovascular event
NCT02416765_exc_T23
Condition
acute coronary syndrome
NCT02416765_exc_T24
Condition
cardiac surgery
NCT02416765_exc_T25
Scope
acute coronary syndrome or cardiac surgery
NCT02416765_exc_T26
Condition
pregnancy
NCT02416765_exc_T27
Temporal
Ongoing
NCT02416765_exc_T28
Condition
hypoglycemic episode
NCT02416765_exc_T29
Qualifier
Severe
NCT02416765_exc_T30
Temporal
within 1 month of screening
NCT02416765_exc_T31
Drug
Agents affecting gastric emptying
NCT02416765_exc_T33
Drug
Motilium
NCT02416765_exc_T34
Drug
Prandase
NCT02416765_exc_T35
Drug
Victoza
NCT02416765_exc_T36
Drug
Byetta
NCT02416765_exc_T37
Drug
Symlin
NCT02416765_exc_T39
Scope
Motilium®, Prandase®, Victoza®, Byetta® and Symlin®
NCT02416765_exc_T40
Drug
oral anti-diabetic agents
NCT02416765_exc_T41
Drug
Metformin
NCT02416765_exc_T42
Drug
SGLT-2 inhibitors
NCT02416765_exc_T43
Drug
DPP-4 inhibitors
NCT02416765_exc_T45
Scope
Metformin, SGLT-2 inhibitors and DPP-4 inhibitors
NCT02416765_exc_T46
Qualifier
stable dose
NCT02416765_exc_T47
Temporal
for 3 months
NCT02416765_exc_T48
Scope
stable dose for 3 months
NCT02416765_exc_T49
Negation
not
NCT02416765_exc_T51
Drug
Oral steroids
NCT02416765_exc_T52
Negation
unless
NCT02416765_exc_T53
Qualifier
stable dose
NCT02416765_exc_T54
Qualifier
low dose
NCT02416765_exc_T55
Multiplier
10 mg or less per day
NCT02416765_exc_T56
Drug
prednisone
NCT02416765_exc_T57
Multiplier
physiological doses
NCT02416765_exc_T58
Multiplier
less than 35 mg/day
NCT02416765_exc_T59
Drug
hydrocortisone
NCT02416765_exc_T60
Drug
Cortef
NCT02416765_exc_T61
Scope
10 mg or less of prednisone per day or physiological doses, less than 35 mg/day, of hydrocortisone Cortef
NCT02416765_exc_T63
Drug
Inhale steroids
NCT02416765_exc_T64
Qualifier
stable dose
NCT02416765_exc_T65
Temporal
in the last month
NCT02416765_exc_T66
Condition
Other medical illness
NCT02416765_exc_T67
Qualifier
serious
NCT02416765_exc_T72
Condition
psychiatric condition
NCT02416765_exc_T73
Qualifier
unstable
NCT02416765_exc_T74
Scope
Other serious medical illness likely to interfere with study participation or with the ability to complete the trial by the judgment of the investigator
NCT02416765_exc_T77
Procedure
closed-loop procedures
NCT02416765_exc_T78
Temporal
during closed-loop procedures
NCT02416765_exc_T79
Reference_point
closed-loop procedures